 | • レポートコード：QFJ1-4348 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、免疫性血小板減少性紫斑病治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エルトロンボパグオラミン、フォスタマチニブ二ナトリウム、GL-2045、アバトロンボパグ、BI-655064、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・免疫性血小板減少性紫斑病治療薬の市場動向 ・企業の競争状況、市場シェア ・免疫性血小板減少性紫斑病治療薬の種類別市場規模と予測2016-2027（エルトロンボパグオラミン、フォスタマチニブ二ナトリウム、GL-2045、アバトロンボパグ、BI-655064、その他） ・免疫性血小板減少性紫斑病治療薬の用途別市場規模と予測2016-2027（病院、診療所、その他） ・免疫性血小板減少性紫斑病治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・免疫性血小板減少性紫斑病治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・免疫性血小板減少性紫斑病治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・免疫性血小板減少性紫斑病治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・免疫性血小板減少性紫斑病治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen Inc.、Baxalta Incorporated、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Eisai、Hansa Medical AB、Immunomedics, Inc.、Intas Pharmaceuticals Ltd.、Jiangsu Hengrui Medicine Co., Ltd.、Merck & Co., Inc.、Momenta Pharmaceuticals, Inc.、Novartis AG、Pfizer Inc.） ・結論 |
Market Analysis and Insights: Global Immune Thrombocytopenic Purpura Therapeutics Market
The global Immune Thrombocytopenic Purpura Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Thrombocytopenic Purpura Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Thrombocytopenic Purpura Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Thrombocytopenic Purpura Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Thrombocytopenic Purpura Therapeutics market.
Global Immune Thrombocytopenic Purpura Therapeutics Scope and Market Size
Immune Thrombocytopenic Purpura Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenic Purpura Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Eltrombopag Olamine
Fostamatinib Disodium
GL-2045
Avatrombopag
BI-655064
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Amgen Inc.
Baxalta Incorporated
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eisai
Hansa Medical AB
Immunomedics, Inc.
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Eltrombopag Olamine
1.2.3 Fostamatinib Disodium
1.2.4 GL-2045
1.2.5 Avatrombopag
1.2.6 BI-655064
1.2.7 Others
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Perspective (2016-2027)
2.2 Immune Thrombocytopenic Purpura Therapeutics Growth Trends by Regions
2.2.1 Immune Thrombocytopenic Purpura Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Immune Thrombocytopenic Purpura Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Immune Thrombocytopenic Purpura Therapeutics Industry Dynamic
2.3.1 Immune Thrombocytopenic Purpura Therapeutics Market Trends
2.3.2 Immune Thrombocytopenic Purpura Therapeutics Market Drivers
2.3.3 Immune Thrombocytopenic Purpura Therapeutics Market Challenges
2.3.4 Immune Thrombocytopenic Purpura Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue
3.1.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenic Purpura Therapeutics Revenue
3.4 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2020
3.5 Immune Thrombocytopenic Purpura Therapeutics Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Type
4.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2022-2027)
5 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Application
5.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size (2016-2027)
6.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type
6.2.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2027)
6.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application
6.3.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2027)
6.4 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country
6.4.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size (2016-2027)
7.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type
7.2.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2027)
7.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application
7.3.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2027)
7.4 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country
7.4.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type
8.2.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application
8.3.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region
8.4.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size (2016-2027)
9.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type
9.2.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application
9.3.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country
9.4.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type
10.2.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application
10.3.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country
10.4.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.1.4 Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 Baxalta Incorporated
11.2.1 Baxalta Incorporated Company Details
11.2.2 Baxalta Incorporated Business Overview
11.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Introduction
11.2.4 Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.2.5 Baxalta Incorporated Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Details
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Eisai
11.5.1 Eisai Company Details
11.5.2 Eisai Business Overview
11.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Introduction
11.5.4 Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.5.5 Eisai Recent Development
11.6 Hansa Medical AB
11.6.1 Hansa Medical AB Company Details
11.6.2 Hansa Medical AB Business Overview
11.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Introduction
11.6.4 Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.6.5 Hansa Medical AB Recent Development
11.7 Immunomedics, Inc.
11.7.1 Immunomedics, Inc. Company Details
11.7.2 Immunomedics, Inc. Business Overview
11.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.7.4 Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.7.5 Immunomedics, Inc. Recent Development
11.8 Intas Pharmaceuticals Ltd.
11.8.1 Intas Pharmaceuticals Ltd. Company Details
11.8.2 Intas Pharmaceuticals Ltd. Business Overview
11.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.8.4 Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.8.5 Intas Pharmaceuticals Ltd. Recent Development
11.9 Jiangsu Hengrui Medicine Co., Ltd.
11.9.1 Jiangsu Hengrui Medicine Co., Ltd. Company Details
11.9.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
11.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.9.4 Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.9.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
11.10 Merck & Co., Inc.
11.10.1 Merck & Co., Inc. Company Details
11.10.2 Merck & Co., Inc. Business Overview
11.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.10.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.10.5 Merck & Co., Inc. Recent Development
11.11 Momenta Pharmaceuticals, Inc.
11.11.1 Momenta Pharmaceuticals, Inc. Company Details
11.11.2 Momenta Pharmaceuticals, Inc. Business Overview
11.11.3 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.11.4 Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.11.5 Momenta Pharmaceuticals, Inc. Recent Development
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Introduction
11.12.4 Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.12.5 Novartis AG Recent Development
11.13 Pfizer Inc.
11.13.1 Pfizer Inc. Company Details
11.13.2 Pfizer Inc. Business Overview
11.13.3 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction
11.13.4 Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
11.13.5 Pfizer Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Eltrombopag Olamine
Table 3. Key Players of Fostamatinib Disodium
Table 4. Key Players of GL-2045
Table 5. Key Players of Avatrombopag
Table 6. Key Players of BI-655064
Table 7. Key Players of Others
Table 8. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Regions (2016-2021)
Table 12. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Regions (2022-2027)
Table 14. Immune Thrombocytopenic Purpura Therapeutics Market Trends
Table 15. Immune Thrombocytopenic Purpura Therapeutics Market Drivers
Table 16. Immune Thrombocytopenic Purpura Therapeutics Market Challenges
Table 17. Immune Thrombocytopenic Purpura Therapeutics Market Restraints
Table 18. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players (2016-2021)
Table 20. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2020)
Table 21. Ranking of Global Top Immune Thrombocytopenic Purpura Therapeutics Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service
Table 25. Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2016-2021)
Table 29. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2016-2021)
Table 33. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 65. Amgen Inc. Company Details
Table 66. Amgen Inc. Business Overview
Table 67. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Product
Table 68. Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 69. Amgen Inc. Recent Development
Table 70. Baxalta Incorporated Company Details
Table 71. Baxalta Incorporated Business Overview
Table 72. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product
Table 73. Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 74. Baxalta Incorporated Recent Development
Table 75. Boehringer Ingelheim GmbH Company Details
Table 76. Boehringer Ingelheim GmbH Business Overview
Table 77. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product
Table 78. Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 79. Boehringer Ingelheim GmbH Recent Development
Table 80. Bristol-Myers Squibb Company Company Details
Table 81. Bristol-Myers Squibb Company Business Overview
Table 82. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product
Table 83. Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 84. Bristol-Myers Squibb Company Recent Development
Table 85. Eisai Company Details
Table 86. Eisai Business Overview
Table 87. Eisai Immune Thrombocytopenic Purpura Therapeutics Product
Table 88. Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 89. Eisai Recent Development
Table 90. Hansa Medical AB Company Details
Table 91. Hansa Medical AB Business Overview
Table 92. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product
Table 93. Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 94. Hansa Medical AB Recent Development
Table 95. Immunomedics, Inc. Company Details
Table 96. Immunomedics, Inc. Business Overview
Table 97. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Product
Table 98. Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 99. Immunomedics, Inc. Recent Development
Table 100. Intas Pharmaceuticals Ltd. Company Details
Table 101. Intas Pharmaceuticals Ltd. Business Overview
Table 102. Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 103. Intas Pharmaceuticals Ltd. Recent Development
Table 104. Jiangsu Hengrui Medicine Co., Ltd. Company Details
Table 105. Jiangsu Hengrui Medicine Co., Ltd. Business Overview
Table 106. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Product
Table 107. Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 108. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 109. Merck & Co., Inc. Company Details
Table 110. Merck & Co., Inc. Business Overview
Table 111. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Product
Table 112. Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 113. Merck & Co., Inc. Recent Development
Table 114. Momenta Pharmaceuticals, Inc. Company Details
Table 115. Momenta Pharmaceuticals, Inc. Business Overview
Table 116. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Product
Table 117. Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 118. Momenta Pharmaceuticals, Inc. Recent Development
Table 119. Novartis AG Company Details
Table 120. Novartis AG Business Overview
Table 121. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product
Table 122. Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 123. Novartis AG Recent Development
Table 124. Pfizer Inc. Company Details
Table 125. Pfizer Inc. Business Overview
Table 126. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Product
Table 127. Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021) & (US$ Million)
Table 128. Pfizer Inc. Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Eltrombopag Olamine Features
Figure 3. Fostamatinib Disodium Features
Figure 4. GL-2045 Features
Figure 5. Avatrombopag Features
Figure 6. BI-655064 Features
Figure 7. Others Features
Figure 8. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Immune Thrombocytopenic Purpura Therapeutics Report Years Considered
Figure 13. Global Immune Thrombocytopenic Purpura Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Immune Thrombocytopenic Purpura Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Regions: 2020 VS 2027
Figure 16. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Regions (2022-2027)
Figure 17. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players in 2020
Figure 18. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2020
Figure 20. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2016-2021)
Figure 21. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2022-2027)
Figure 22. North America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Type (2016-2027)
Figure 24. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Application (2016-2027)
Figure 25. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Type (2016-2027)
Figure 30. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Application (2016-2027)
Figure 31. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2016-2027)
Figure 32. Germany Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2016-2027)
Figure 42. China Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Type (2016-2027)
Figure 50. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Application (2016-2027)
Figure 51. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2016-2027)
Figure 52. Mexico Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2016-2027)
Figure 58. Turkey Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Amgen Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 62. Baxalta Incorporated Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 63. Boehringer Ingelheim GmbH Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 64. Bristol-Myers Squibb Company Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 65. Eisai Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 66. Hansa Medical AB Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 67. Immunomedics, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 68. Intas Pharmaceuticals Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 69. Jiangsu Hengrui Medicine Co., Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 70. Merck & Co., Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 71. Momenta Pharmaceuticals, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 72. Novartis AG Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 73. Pfizer Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
免疫性血小板減少性紫斑病治療薬のグローバル市場調査 2019年 The global Immune Thrombocytopenic Purpura Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Immune Thrombocytopenic Purpura Therapeutics volume and value at global level, regional level …- 世界の免疫性血小板減少症治療薬市場規模・現状・予測（2021年-2027年） Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for appr…
- 世界のアテローム性動脈硬化症治療薬市場規模・現状・予測（2021年-2027年） Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as th…
- 免疫性血小板減少薬のグローバル市場：規模・現状・予測2019-2025 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for appro…
- 免疫性血小板減少薬のグローバル市場：規模・現状・予測2019-2025 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for appro…